UKCA (United Kingdom Conformity Assessed) for Medical Devices

Access the UK Market with Confidence—Without Regulatory Delays

Following Brexit, the United Kingdom introduced the UKCA (UK Conformity Assessed) marking as the regulatory pathway for medical devices placed on the market in Great Britain (England, Scotland, and Wales).

This is not just a rebranding of CE marking—it represents a distinct regulatory framework governed by the UK Medical Devices Regulations 2002 (UK MDR 2002), with evolving requirements and increasing expectations around post-market surveillance and lifecycle compliance.

RQMIS helps medical device companies navigate UKCA requirements efficiently—so you can enter and sustain access to the UK market without unnecessary delays or rework.

What Is UKCA—and Why It Matters

The UKCA mark is a conformity marking that demonstrates your device meets UK regulatory requirements for safety, performance, and intended use.

To place a device on the Great Britain market, manufacturers must:

• Comply with UK MDR 2002 (as amended)
• Complete a conformity assessment (with a UK Approved Body where required)
• Prepare technical documentation and declaration of conformity
• Register devices with the MHRA
• Apply the UKCA marking

Without this, your product cannot legally be marketed in Great Britain.

UKCA vs EU MDR: What’s Different

Many companies assume UKCA is identical to EU MDR. It’s not.

Key differences include:

• UKCA is based on UK MDR 2002 (derived from EU Directives, not MDR/IVDR)
• Requires a UK Responsible Person (UKRP) for non-UK manufacturers
• Uses UK Approved Bodies, not EU Notified Bodies
• Applies only to Great Britain (Northern Ireland follows CE/UKNI rules)
• Transitional timelines allow temporary CE acceptance—but this is ending

Manufacturers must now plan for a dual-market strategy (UK + EU) if they want full European access.

The Challenge

Most companies underestimate UKCA.

They assume:

• CE marking is enough
• Requirements are identical to EU MDR
• Transition timelines will continue indefinitely

In reality, companies face:

• Confusion between UK and EU regulatory expectations
• Gaps in technical documentation and labeling
• Delays in Approved Body availability
• Lack of alignment between UK registration, QMS, and post-market requirements

This leads to market access delays and increased regulatory risk.

How RQMIS Helps

We don’t just guide you through UKCA—we build a clear, executable pathway to UK market access and ongoing compliance.

UKCA Gap Assessment & Strategy

We identify where you stand and define what’s required.

• Alignment to UK MDR 2002 requirements
• Technical documentation gap analysis
• Regulatory pathway and classification strategy
• UK vs EU regulatory alignment planning

Technical Documentation & Compliance

We prepare documentation that supports approval and withstands scrutiny.

• Technical files aligned with UK MDR
• Risk management (ISO 14971)
• Clinical evaluation and evidence strategy
• Labeling and IFU alignment

Conformity Assessment & UK Approved Body Support

We guide you through certification requirements.

• Identification of required conformity assessment route
• Coordination with UK Approved Bodies
• Preparation for audits and reviews
• Support through certification

MHRA Registration & UK Responsible Person (UKRP)

Market access depends on proper registration and representation.

• MHRA device registration
• UK Responsible Person setup and support
• Regulatory liaison and communication

All devices must be registered with the MHRA before being placed on the market.

Post-Market Surveillance (PMS) & Lifecycle Compliance

Like EU MDR, UKCA is moving toward a lifecycle-based regulatory model.

Manufacturers must:

• Monitor product performance in real-world use
• Investigate incidents and report to MHRA
• Maintain complaint handling and vigilance systems
• Continuously update documentation and risk management

New UK regulations are strengthening PMS expectations, including PMS plans, reports, and faster vigilance timelines.

A Lifecycle Approach to UK Compliance

UKCA is not a one-time certification—it’s an ongoing compliance system.

Manufacturers must demonstrate that their device:

• Is safe and effective at launch
• Remains safe and effective over time
• Is actively monitored and improved based on real-world data

This is where most companies fall short—and where RQMIS creates long-term value.

The Outcome

With RQMIS, you can:

• Achieve UKCA compliance faster
• Avoid delays in MHRA registration and approval
• Align UK and EU strategies efficiently
• Reduce regulatory risk and rework
• Maintain continuous compliance after market entry

Why RQMIS

• Deep expertise across UK, EU, and global regulatory frameworks
• Integrated regulatory, clinical, and quality strategy
• Proven ability to accelerate approvals and resolve gaps
• Practical execution—not just advisory

We don’t just help you meet UKCA requirements—we help you operate successfully within them.

Don’t Let UKCA Delay Your Market Entry

The UK is a critical market—but only if you can access it efficiently.